Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)

Phase 4

Completed

Conditions: Spondyloarthritis

Interventions: Biological: Golimumab
Biological: Placebo

First Posted Date: 2017-08-18

Last Posted Date: 2023-07-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 323

Registration Number: NCT03253796

Locations: 🇨🇿
CCBR Ostrava s.r.o. ( Site 0001), Ostrava, Czechia
🇨🇿
FN Brno ( Site 0005), Brno, Czechia
🇷🇴
Spitalul Clinic Sfanta Maria ( Site 0182), Bucharest, Romania

and more 68 locations

Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

Phase 1

Terminated

Conditions: Solid Tumor
Lymphoma

Interventions: Drug: MK-2118 (IT)
Drug: MK-2118 (SC)
Biological: Pembrolizumab

First Posted Date: 2017-08-15

Last Posted Date: 2024-07-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 140

Registration Number: NCT03249792

Locations: 🇺🇸
UCLA ( Site 0003), Los Angeles, California, United States
🇺🇸
MD Anderson Cancer Centr. ( Site 0006), Houston, Texas, United States
🇺🇸
University of California San Diego Moores Cancer Center ( Site 0004), La Jolla, California, United States

and more 5 locations

Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

Phase 3

Completed

Conditions: Varicella

Interventions: Biological: VARIVAX® 2016 Commercial Process
Biological: VARIVAX® PE34 Process
Biological: M-M-R II®

First Posted Date: 2017-08-04

Last Posted Date: 2021-01-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 600

Registration Number: NCT03239873

Locations: 🇺🇸
Tanner Clinic ( Site 0010), Layton, Utah, United States
🇺🇸
Wee Care Pediatrics-Roy ( Site 0043), Roy, Utah, United States
🇺🇸
Premier Health Research Center, LLC ( Site 0044), Downey, California, United States

and more 34 locations

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Phase 1

Completed

Conditions: Suspected or Documented Gram-negative Bacterial Infection

Interventions: Drug: IMI/REL FDC

First Posted Date: 2017-07-27

Last Posted Date: 2024-02-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 47

Registration Number: NCT03230916

Locations: 🇺🇸
The Children's Hospital of Philadelphia ( Site 1318), Philadelphia, Pennsylvania, United States
🇺🇸
Seattle Childrens Hospital ( Site 1321), Seattle, Washington, United States
🇺🇦
Odessa Regional Children Clinical Hospital ( Site 1203), Odesa, Odeska Oblast, Ukraine

and more 30 locations

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

Phase 2

Completed

Conditions: Pyelonephritis
Complicated Urinary Tract Infection

Interventions: Drug: Ceftolozane/Tazobactam
Drug: Meropenem

First Posted Date: 2017-07-26

Last Posted Date: 2023-05-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 134

Registration Number: NCT03230838

Locations: 🇺🇸
SUNY Upstate Medical University Hospital ( Site 2510), Syracuse, New York, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 2519), Chicago, Illinois, United States
🇺🇸
Baylor College Of Medicine ( Site 2515), Houston, Texas, United States

and more 49 locations

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Phase 3

Active, not recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Biological: Pembrolizumab
Drug: Placebo
Drug: Cisplatin
Drug: Capecitabine
Drug: Docetaxel
Drug: 5-fluorouracil
Drug: Oxaliplatin
Drug: Leucovorin

First Posted Date: 2017-07-18

Last Posted Date: 2025-02-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1007

Registration Number: NCT03221426

Locations: 🇺🇸
Fox Chase Cancer Center ( Site 0006), Philadelphia, Pennsylvania, United States
🇨🇦
Cross Cancer Institute ( Site 0033), Edmonton, Alberta, Canada
🇨🇦
Jewish General Hospital ( Site 0034), Montreal, Quebec, Canada

and more 168 locations

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Biological: Pembrolizumab
Biological: Daratumumab

First Posted Date: 2017-07-18

Last Posted Date: 2019-03-25

Lead Sponsor: Merck Sharp & Dohme LLC

Registration Number: NCT03221634

Locations: 🇫🇷
Hopital Saint-Louis ( Site 0202), Paris, France
🇮🇱
Rambam Medical Center ( Site 0700), Haifa, Israel
🇮🇱
Sourasky Medical Center ( Site 0701), Tel Aviv, Israel

and more 20 locations

A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

Phase 1

Completed

Conditions: Gram-Positive Infections

Interventions: Drug: IV Tedizolid Phosphate
Drug: Oral Suspension Tedizolid Phosphate

First Posted Date: 2017-07-14

Last Posted Date: 2025-02-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 47

Registration Number: NCT03217565

Locations: 🇧🇬
MHAT Rousse-Neonatology ( Site 2213), Ruse, Bulgaria
🇧🇬
Multiprofile Hospital for Active Treatment - Ruse ( Site 2204), Ruse, Bulgaria
🇺🇸
Arkansas Children's Hospital ( Site 1012), Little Rock, Arkansas, United States

and more 27 locations

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Phase 2

Completed

Conditions: Complicated Intra-Abdominal Infection

Interventions: Drug: Ceftolozane/Tazobactam
Drug: Meropenem
Drug: Placebo for Metronidazole
Drug: Metronidazole

First Posted Date: 2017-07-13

Last Posted Date: 2023-05-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 94

Registration Number: NCT03217136

Locations: 🇿🇦
Red Cross War Memorial Children's Hospital ( Site 1902), Cape Town, Western Cape, South Africa
🇲🇾
Universiti Kebangsaan Malaya Medical Centre ( Site 1101), Cheras, Johor, Malaysia
🇺🇸
Children's Hospital of Orange County ( Site 2502), Orange, California, United States

and more 47 locations

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

Phase 3

Completed

Conditions: Esophageal Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Placebo
Drug: Cisplatin
Drug: 5-FU

First Posted Date: 2017-06-16

Last Posted Date: 2024-10-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 749

Registration Number: NCT03189719

Locations: 🇿🇦
The Medical Oncology Centre of Rosebank ( Site 2506), Johannesburg, Gauteng, South Africa
🇪🇸
Hospital Universitario Central de Asturias ( Site 0708), Oviedo, Asturias, Spain
🇺🇸
University of Maryland Medical Center ( Site 0013), Baltimore, Maryland, United States

and more 186 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy